Curated News
By: NewsRamp Editorial Staff
March 31, 2026
Vycor Medical Posts 2025 Profit Surge on Neurosurgery Device Growth
TLDR
- Vycor Medical's 18% revenue growth and international expansion demonstrate strong market positioning for investors seeking medical technology opportunities.
- Vycor Medical's 2025 financials show $1.86M revenue with 83% gross margin, transitioning from a $9K loss to $33.9K operating profit through strategic international growth.
- Vycor's medical devices reduce brain tissue damage and hospital stays while NovaVision's home-based therapy helps stroke patients regain vision, improving recovery outcomes globally.
- Seven new studies in 2025 brought Vycor's VBAS research to 50 papers, validating reduced brain damage across four countries including Japan and Mexico.
Impact - Why it Matters
This news matters because it highlights the financial viability and clinical validation of innovative medical technologies addressing critical neurological conditions. For patients suffering from brain tumors or visual impairments from stroke, Vycor's products represent tangible advances: the VBAS system offers neurosurgeons a tool to perform less invasive procedures with potentially better outcomes and shorter recovery times, while NovaVision's therapies provide hope for vision recovery where few options exist. The shift to profitability and strong international growth for VBAS suggests the technology is gaining global acceptance, which could accelerate its adoption and benefit more patients worldwide. Furthermore, the successful validation of home-based NeuroEyeCoach therapy aligns with the massive trend toward telehealth and remote patient monitoring, potentially making effective vision rehabilitation more accessible and affordable. For investors, the turnaround from an operating loss to profit, coupled with growing clinical evidence, indicates a company potentially moving from development to sustainable commercial execution in specialized, high-need medical markets.
Summary
Vycor Medical, Inc. (OTCQB: VYCO), a medical technology company based in Boca Raton, Florida, has announced its financial results for the fiscal year ending December 31, 2025. The company operates through two distinct business units: Vycor Medical, which manufactures the FDA-cleared ViewSite™ Brain Access System (VBAS) for minimally invasive neurosurgery, and NovaVision®, a division in development that offers vision rehabilitation therapies for patients recovering from stroke or brain injury. The core financial message reveals a company in transition, with total revenue increasing by 17% to $1,863,400, driven primarily by an 18% growth in the Vycor Medical division's sales, largely from international markets. The company achieved a significant turnaround in operating profit, reporting $33,900 compared to an operating loss of $9,145 in 2024, while non-GAAP operating profit more than doubled to $145,881.
The key players in this financial narrative are the Vycor Medical division's VBAS product and the NovaVision division's NeuroEyeCoach program. The VBAS system demonstrated strong clinical validation in 2025 with seven new peer-reviewed studies published, bringing the total to 50, with research from the US, UK, Japan, and Mexico highlighting reduced brain tissue damage and improved patient outcomes. For an overview of Vycor Medical's VBAS, interested parties can view the VBAS Video. Simultaneously, a pivotal clinical study on NovaVision's NeuroEyeCoach validated its effectiveness for home-based therapy, a crucial finding as healthcare systems worldwide push for remote digital health solutions. For an overview of NovaVision, the NovaVision Video provides further insight. Financially, while the Vycor Medical division was profitable, generating $493,787 in operating income, the NovaVision division reported an operating loss of $183,878 as it remains in development, though it maintained a high gross margin of 93%.
The detailed financial results show a company strategically investing in growth, with gross profit increasing 11% to $1,498,295, though the gross margin decreased from 89% to 83% due to costs associated with validating new production and a higher mix of international sales. Management emphasized non-GAAP financial measures, which exclude non-cash items like depreciation and stock-based compensation, to present a clearer picture of core operational performance, showing non-GAAP cash operating expenses of $1,415,226. The company maintains an active online presence for stakeholders seeking the latest information, directing them to www.vycormedical.com, www.vycorvbas.com, or www.novavision.com. The original release was published on www.newmediawire.com, providing the official source for this financial disclosure and forward-looking statements about the company's future trajectory in the competitive medical device and therapy markets.
Source Statement
This curated news summary relied on content disributed by NewMediaWire. Read the original source here, Vycor Medical Posts 2025 Profit Surge on Neurosurgery Device Growth
